Cleveland State University
Cleveland, Ohio, 44115, United States
Location status: Recruiting
Location contact
Douglas A Wajda
CONTACT
NCT Number: NCT05964829
The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).
Interested in participating?
Request Info22 year–75 year
All sexes
Interventional
Not applicable
Cleveland, Ohio, 44115, United States
Location status: Recruiting
Douglas A Wajda
CONTACT
The randomized within-participants crossover 12-week study aims to demonstrate the clinical impact of the Cionic Neural Sleeve for individuals diagnosed with MS.
Physical measurements, performance-based tests, and questionnaire responses will be recorded. These include physical activity recorded by the Cionic Neural Sleeve; in-person tests measuring disability, spasticity and balance; and questionnaires gauging perceived walking ability, quality of life, and physical and psychological impact of MS.
All participants will be assigned a Cionic Neural Sleeve on the most impacted leg for 6 weeks, and prescribed a home-based intervention of 15 minutes of walking for 5 days a week for 12 weeks. The Cionic Neural Sleeve will be worn for 6 weeks of the study while following the walking program.
Participants will be randomized to one of two groups: A or B. Group A will follow the walking program and wear the Neural Sleeve to receive stimulation assisted walking from the Neural Sleeve for 6 weeks. Group B will follow the walking program for 6 weeks. After 6 weeks, participants in each group will cross over to the other group.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks.
15 minutes of walking for 5 days per week for 6 weeks
Time frame: Day 0, Week 6, Week 12
The Timed 25-Foot Walk Test (T25FWT) to record duration of time to walk a distance of 25 feet, measured in seconds. The score is the average of two successive trials.
Time frame: Day 0, Week 6, Week 12
Multiple Sclerosis Walking Scale-12 (MSWS-12) to measure perceived impact of MS on walking ability, measured by score. Scores on the MSWS-12 range from 12-60 and transformed to a scale with a range from 0 to 100, with high scores indicative of a greater impact of MS on walking.
Time frame: Day 0, Week 6, Week 12
A 9-item survey, Patient-Determined Disease Steps (PDDS), will measure of disability status in individuals with MS. The PDDS ranges from 0 to 8, with higher values indicative of higher levels of disability.
Time frame: During allocation to receive the functional electrical stimulation arm
Collected by the usage log of the device, measured in steps per day
Time frame: During allocation to receive the functional electrical stimulation arm
Collected by the usage log of the device, measured in duration of activity.
Time frame: Day 0, Week 6, Week 12
The Euroqol 5 Dimension 5 Level (EQ-5D-5L) questionnaire describes health profiles using different domains, measured by a 5-digit code. Single-digit numbers of the dimensions range from 1 to 5, with 1 indicative of no problem and 5 indicative of extreme problems in that domain.
Time frame: Day 0, Week 6, Week 12
Multiple Sclerosis Impact Scale-29 (MSIS-29) questionnaire to measure the physical and psychological impact of MS, measured by score. Scores on the MSIS-29 are transformed into a score out of 100, with higher scores indicative of greater degree of disability.
Time frame: Day 0, Week 6, Week 12
Modified Fatigue Impact Scale (MFIS) survey to measure the effects of fatigue in physical, cognitive, and psychosocial functioning. MFIS score ranges from 0 to 84, with high scores indicative of a greater impact of fatigue on activities.
Time frame: Day 0, Week 6, Week 12
A trained clinician will administer the Modified Ashworth Scale (MAS) to assess for muscle tone and spasticity. Scores of the MAS range from 0 to 4, with high scores representative of increased muscle tone and spasticity.
Time frame: Day 0, Week 6, Week 12
Strength assessment of the ankle dorsiflexors, hamstrings, and quadriceps muscles using a handheld dynamometer in seated or laying in prone, measured in Newtons.
Time frame: Day 0, Week 6, Week 12
Ankle plantarflexor strength will be measured by maximal repetitions of single leg heel raises.
Time frame: Day 0, Week 6, Week 12
Range of motion of the ankle, knee, and hips will be assessed by a trained clinician using a handheld goniometer.
Time frame: Day 0, Week 6, Week 12
Measured via the 6-minute walk test, where subjects will walk as far as possible for 6 minutes, measured in meters.
Time frame: Day 0, Week 6, Week 12
Measured using force platform posturography in standing to quantify postural sway. There will be four 30-second trials with eyes open standing as still as possible.
Time frame: From enrollment to end of treatment at 12 weeks
Measured using a self-reported fall diary and a survey, the Hopkins Fall Grading Scale, a 4-point scale to grade the nature and severity of a fall. Higher grades represent increased severity and impact of injurious falls.
Time frame: Day 0, Week 6, Week 12
Measured by changes in dose intensities of prescribed medication(s).
Time frame: Day 0, Week 6, Week 12
Measured using the questionnaire, the Numeric Pain Rating Scale (NPRS), an 11-point numeric scale ranging from 0 to 10, with 0 being no pain and 10 being worst pain imaginable.
Time frame: From enrollment to end of treatment at 12 weeks
Subjects will record their weekly physical activity using the Godin-Leisure Time Exercise Questionnaire (GLTEQ), measured by score. Scores less than 14 units are interpreted as insufficiently active/sedentary, while scores between 14 and 23 are interpreted as moderately active, and scores greater than 24 units are interpreted as active.
Contact information is provided by the study sponsor or research team.
Douglas A Wajda, PhD
CONTACT
Rebecca Webster, PhD
CONTACT
Cionic, Inc.
Industry
A Crossover Study Evaluating the Impact of the Cionic Neural Sleeve on Mobility, Disability, Fall Risk, and Physical Activity in Multiple Sclerosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02403570
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Turku, Finland
View Trial DetailsNCT06390930
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Chicago, Illinois, United States
View Trial DetailsNCT06526364
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Basel, Switzerland
View Trial DetailsNCT06516458
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Chicago, Illinois, United States
View Trial Details